Clearpoint Neuro, Inc. income statement
In fiscal 2025, Clearpoint Neuro, Inc. reported revenue of $37.0m, up 17.8% on the year before, operating income of −$24.2m (a -65.4% margin) and net income of −$25.5m, or −$0.90 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 4 | 5 | 4 | 4 | 5 | 6 | 7 | 7 | 11 | 13 | 16 | 21 | 24 | 31 | 37 | 45 |
| Cost of revenue | — | — | — | — | — | — | — | 3 | 2 | 4 | 4 | 5 | 7 | 10 | 12 | 14 | 18 |
| Gross profit | — | — | — | — | — | — | — | 4 | 5 | 7 | 9 | 11 | 14 | 14 | 19 | 23 | 28 |
| Research and development | 6 | 4 | 2 | 3 | 3 | 2 | 3 | 3 | 2 | 3 | 5 | 9 | 11 | 12 | 12 | 14 | 16 |
| Selling, general and administrative | 5 | 5 | 6 | 7 | 8 | 8 | 4 | 4 | 4 | 4 | 5 | 8 | 10 | 12 | 12 | 16 | 20 |
| Operating income | −10 | −6 | −3 | −7 | −5 | −9 | −7 | −6 | −5 | −5 | −6 | −13 | −16 | −22 | −20 | −24 | −32 |
| Interest expense | 2 | 2 | 3 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | — | 1 | 2 | 5 |
| Net interest income | — | — | — | — | — | — | — | — | — | — | — | — | −0 | 0 | 1 | — | — |
| Income before tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | −19 | −25 | −36 |
| Income tax | — | — | 0 | 0 | 0 | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | −0 |
| Net income | −9 | −8 | −6 | −7 | −5 | −8 | −8 | −7 | −6 | −6 | −7 | −14 | −16 | −22 | −19 | −26 | −36 |
| Diluted EPS | −$56.00 | −$0.52 | −$0.15 | −$0.12 | −$0.08 | −$4.48 | −$2.93 | −$0.93 | −$0.56 | −$0.42 | −$0.43 | −$0.69 | −$0.68 | −$0.90 | −$0.70 | −$0.90 | −$1.21 |
| Diluted shares (average) | — | — | 1m | 1m | 1m | 2m | 3m | 8m | 11m | 13m | 16m | 21m | 24m | 25m | 27m | 28m | 30m |
| EBITDA | −9 | −6 | −3 | −7 | −5 | −9 | −7 | −6 | −5 | −4 | −6 | −13 | −16 | −22 | −19 | −23 | −32 |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8 | 8 | 9 | 9 | 10 | 12 | 11 | 12 |
| Cost of revenue | 3 | 3 | 4 | 3 | 4 | 4 | 4 | 5 |
| Gross profit | 5 | 5 | 6 | 6 | 6 | 8 | 7 | 7 |
| Research and development | 3 | 3 | 4 | 3 | 3 | 5 | 5 | 4 |
| Selling, general and administrative | 3 | 4 | 3 | 4 | 5 | 5 | 6 | 4 |
| Operating income | −6 | −6 | −6 | −5 | −7 | −8 | −10 | −6 |
| Interest expense | — | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Net interest income | 0 | 0 | −0 | −1 | — | — | — | — |
| Income before tax | −5 | −6 | −6 | −6 | −8 | −10 | −11 | −7 |
| Income tax | −0 | 0 | 0 | 0 | 0 | 0 | −0 | −0 |
| Net income | −5 | −6 | −6 | −6 | −8 | −10 | −11 | −7 |
| Diluted EPS | −$0.20 | −$0.22 | −$0.21 | −$0.21 | −$0.27 | −$0.32 | −$0.38 | −$0.24 |
| EBITDA | −5 | −6 | −5 | −5 | −7 | −8 | −10 | −6 |
Compare with peers
- Koru Medical Systems, Inc. income statement
- Trisalus Life Sciences, Inc. income statement
- Sanuwave Health, Inc. income statement
- Myomo, Inc. income statement
- Senseonics Holdings, Inc. income statement
Head to head: CLPT vs KRMDCLPT vs TLSICLPT vs SNWVCLPT vs SENS
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies